AGC Biologics Adds Mammalian Production Capacity in Japan
The new facility will include comprehensive mammalian process development and manufacturing capabilities.
AGC Biologics, a clinical and commercial manufacturer of therapeutic proteins, announced on Sept. 20, 2018 that it will establish a new process development and manufacturing facility at its contract development and manufacturing organization (CDMO) facility in Chiba, Japan, as part of its ongoing program to expand its production capacities globally.
The new facility will contain single-use bioreactors at the 500- and 2000-L scale and will be suited for the production of monoclonal antibodies, fusion proteins, and other types of therapeutic proteins. The facility is expected to be operational in the second half of 2019.
The company currently provides mammalian protein process development and manufacturing services from its facilities in Bothell, WA; Berkeley, CA; and Copenhagen, Denmark, as well as microbial process development and manufacturing services from its facilities in Heidelberg, Germany; Copenhagen, Denmark; and Chiba, Japan. The company will leverage its experience and expertise with mammalian production systems to establish these services at its site in Japan.
“This is a key investment for AGC Biologics that will expand our capabilities and reinforce our leadership position in the Japanese CDMO marketplace.” said Gustavo Mahler, PhD, CEO of AGC Biologics, in a company press release. “Our new mammalian capabilities will represent a unique and convenient option for companies in Asia seeking mammalian production services nearby and for United States and European companies seeking production in Asia.”
Source: AGC Biologics
